FDA Allows Tysabri Use With Mandatory Restrictions

More information on Tysabri, including the new label and a summary of the risk- minimization action plan, is available at www.fda.gov/cder/drug/infopage/natalizumab/default.htm. Information on the program can also be obtained by calling the company at 1-800-456-2255.